MYC and lymphoma: Given the importance of MYC in driving metabolic reprogramming in lymphoma progress, oncogenic HSP90 inhibitors could reverse the immunosuppressive effects on the lymphoma microenvironment and thus potentially improve efficacy of lymphoma immunotherapy.